Although the discovery of proprotein convertase subtilisin/ kexin type 9 (PCSK9) and development of therapeutic antagonists represent a major triumph of modern clinical medicine, efforts to implement PCSK9 inhibitors (PCSK9i) in patient care have been sobering. This practical guide examines the barriers and opportunities for the successful application of pharmacological inhibition of PCSK9 in clinical practice through introduction of a new model of care delivery-the PCSK9i clinic.
|Original language||English (US)|
|Number of pages||3|
|State||Published - Aug 1 2017|
- Patient care
- Secondary prevention
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine